{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T15:12:55Z","timestamp":1721229175220},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fragmented cytokeratin 18 (fCK18) released from epithelial cells undergoing apoptosis is widely studied in various diseases. However, fCK18 measurement is not utilized in clinical practice due to imprecise disease-state cutoff values. Therefore, we set out to generate new monoclonal antibodies (mAbs) and a recombinant fCK18 (rfCK18) calibrator in an effort to develop a highly sensitive chemiluminescent enzyme immunoassay (CLEIA). New capture mAb (K18-624) had a high binding ability compared to the current commercial antibody. New detection mAb (K18-328) recognized 323S-340G of CK18. A rfCK18 was expressed in the soluble fraction of <jats:italic>E. coli<\/jats:italic> when the N-terminal region (260 amino acid residues) of CK18 was truncated. Analysis of performance and measurement of human fCK18 were evaluated using K18-624 and K18-328 in a highly sensitive CLEIA. The coefficients of variation (CV) for within-run and between-day repeatability were below 10% and the recoveries were in the range of 15%. The detection sensitivity was 0.056\u00a0ng\/mL. Serum fCK18 levels were significantly increased in non-alcoholic steatohepatitis (NASH) patients when compared to healthy individuals. Our new fCK18 mAbs showed high affinity and sensitivity. CLEIA using our new antibodies will be useful in measuring fCK18 in human blood thereby generating accurate clinical diagnoses of human liver diseases.<\/jats:p>","DOI":"10.1038\/s41598-021-97439-5","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T10:03:16Z","timestamp":1631613796000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Development of a highly sensitive chemiluminescent enzyme immunoassay for fragmented cytokeratin 18 using new antibodies"],"prefix":"10.1038","volume":"11","author":[{"given":"Minori","family":"Yamada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Okuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuji","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,14]]},"reference":[{"key":"97439_CR1","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1083\/jcb.138.6.1379","volume":"138","author":"C Caul\u00edn","year":"1997","unstructured":"Caul\u00edn, C., Salvesen, G. S. & Oshima, R. G. Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J. Cell Biol. 138, 1379\u20131394 (1997).","journal-title":"J. Cell Biol."},{"key":"97439_CR2","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1158\/0008-5472.CAN-03-2455","volume":"64","author":"G Kramer","year":"2004","unstructured":"Kramer, G. et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res. 64, 1751\u20131756 (2004).","journal-title":"Cancer Res."},{"key":"97439_CR3","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0959-8049(02)00865-1","volume":"39","author":"T Ueno","year":"2003","unstructured":"Ueno, T. et al. Measurement of an apoptotic product in the sera of breast cancer patients. Eur. J. Cancer 39, 769\u2013774 (2003).","journal-title":"Eur. J. Cancer"},{"key":"97439_CR4","doi-asserted-by":"publisher","first-page":"1783046","DOI":"10.1080\/2162402X.2020.1783046","volume":"9","author":"P Sirni\u00f6","year":"2020","unstructured":"Sirni\u00f6, P. et al. Systemic inflammation is associated with circulating cell death released keratin 18 fragments in colorectal cancer. Oncoimmunology 9, 1783046. https:\/\/doi.org\/10.1080\/2162402X.2020.1783046 (2020).","journal-title":"Oncoimmunology"},{"key":"97439_CR5","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.11.015","volume":"28","author":"T Molnar","year":"2019","unstructured":"Molnar, T. et al. Subacute elevation of plasma level of caspase-cleaved cytokeratin-18 is associated with hemorrhagic transformation and functional outcome in ischemic stroke. J. Stroke Cerebrovasc. Dis. 28, 719\u2013727 (2019).","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"97439_CR6","doi-asserted-by":"publisher","first-page":"e30165","DOI":"10.5812\/atr.30165","volume":"5","author":"L Lorente","year":"2015","unstructured":"Lorente, L. New prognostic biomarkers in patients with traumatic brain injury. Arch. Trauma Res. 5, e30165. https:\/\/doi.org\/10.5812\/atr.30165 (2015).","journal-title":"Arch. Trauma Res."},{"key":"97439_CR7","doi-asserted-by":"publisher","first-page":"4535","DOI":"10.1182\/blood-2006-10-049817","volume":"110","author":"T Luft","year":"2007","unstructured":"Luft, T. et al. Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease. Blood 110, 4535\u20134542 (2007).","journal-title":"Blood"},{"key":"97439_CR8","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.jhep.2013.12.026","volume":"60","author":"A Eguchi","year":"2014","unstructured":"Eguchi, A., Wree, A. & Feldstein, A. E. Biomarkers of liver cell death. J. Hepatol. 60, 1063\u20131074 (2014).","journal-title":"J. Hepatol."},{"key":"97439_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease\u2014Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73\u201384 (2016).","journal-title":"Hepatology"},{"key":"97439_CR10","doi-asserted-by":"publisher","first-page":"e0140908","DOI":"10.1371\/journal.pone.0140908","volume":"10","author":"EL Anderson","year":"2015","unstructured":"Anderson, E. L. et al. The prevalence of non-alcoholic fatty liver disease in children and adolescents: A systematic review and meta-analysis. PLoS ONE 10, e0140908. https:\/\/doi.org\/10.1371\/journal.pone.0140908 (2015).","journal-title":"PLoS ONE"},{"key":"97439_CR11","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/hep.23050","volume":"50","author":"AE Feldstein","year":"2009","unstructured":"Feldstein, A. E. et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study. Hepatology 50, 1072\u20131078 (2009).","journal-title":"Hepatology"},{"key":"97439_CR12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/MCG.0b013e3181bdefe2","volume":"44","author":"M Tsutsui","year":"2010","unstructured":"Tsutsui, M. et al. Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels. J. Clin. Gastroenterol. 44, 440\u2013447 (2010).","journal-title":"J. Clin. Gastroenterol."},{"key":"97439_CR13","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328\u2013357 (2018).","journal-title":"Hepatology"},{"key":"97439_CR14","doi-asserted-by":"publisher","first-page":"e0238717","DOI":"10.1371\/journal.pone.0238717","volume":"15","author":"J Lee","year":"2020","unstructured":"Lee, J. et al. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis. PLoS ONE 15, e0238717. https:\/\/doi.org\/10.1371\/journal.pone.0238717 (2020).","journal-title":"PLoS ONE"},{"key":"97439_CR15","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/ajg.2013.350","volume":"109","author":"H Bantel","year":"2014","unstructured":"Bantel, H., John, K. & Schulze-Osthoff, K. Robust detection of liver steatosis and staging of NAFLD by an improved ELISA for serum cytokeratin-18 fragments. Am. J. Gastroenterol. 109, 140\u2013141 (2014).","journal-title":"Am. J. Gastroenterol."},{"key":"97439_CR16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J","volume":"187","author":"MPG Leers","year":"1999","unstructured":"Leers, M. P. G. et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo- epitope exposed during early apoptosis. J. Pathol. 187, 567\u2013572 (1999).","journal-title":"J. Pathol."},{"key":"97439_CR17","first-page":"4191","volume":"7","author":"Y Aida","year":"2014","unstructured":"Aida, Y. et al. Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease. Int. J. Clin. Exp. Med. 7, 4191\u20134198 (2014).","journal-title":"Int. J. Clin. Exp. Med."},{"key":"97439_CR18","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1158\/1078-0432.CCR-07-0009","volume":"13","author":"MH Olofsson","year":"2007","unstructured":"Olofsson, M. H. et al. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin. Cancer Res. 13, 3198\u20133206 (2007).","journal-title":"Clin. Cancer Res."},{"key":"97439_CR19","doi-asserted-by":"publisher","DOI":"10.21767\/2386-5180.100032","author":"S Bhatnagar","year":"2015","unstructured":"Bhatnagar, S. Evaluation of four tumor markers (CEA, AFP, CA125 and CA19-9) on Sysmex HISCL- 5000 immunoassay analyzer. Ann. Clin. Lab. Res. https:\/\/doi.org\/10.21767\/2386-5180.100032 (2015).","journal-title":"Ann. Clin. Lab. Res."},{"key":"97439_CR20","doi-asserted-by":"publisher","first-page":"14352","DOI":"10.1038\/s41598-017-14747-5","volume":"7","author":"J Liu","year":"2017","unstructured":"Liu, J. et al. Serum levels of M2BPGi as short-term predictors of hepatocellular carcinoma in untreated chronic hepatitis B patients. Sci. Rep. 7, 14352. https:\/\/doi.org\/10.1038\/s41598-017-14747-5 (2017).","journal-title":"Sci. Rep."},{"key":"97439_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jhep.2013.07.042","volume":"60","author":"K Cusi","year":"2014","unstructured":"Cusi, K. et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J. Hepatol. 60, 167\u2013174 (2014).","journal-title":"J. Hepatol."},{"key":"97439_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","volume":"73","author":"SA Harrison","year":"2020","unstructured":"Harrison, S. A. et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. J. Hepatol. 73, 26\u201339 (2020).","journal-title":"J. Hepatol."},{"key":"97439_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/apt.15030","volume":"49","author":"M Shiffman","year":"2019","unstructured":"Shiffman, M. et al. Randomised clinical trial: Emricasan versus placebo significantly decreases ALT and caspase 3\/7 activation in subjects with non-alcoholic fatty liver disease. Aliment Pharmacol. Ther. 49, 64\u201373 (2019).","journal-title":"Aliment Pharmacol. Ther."},{"key":"97439_CR24","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1002\/hep.29477","volume":"67","author":"SL Friedman","year":"2018","unstructured":"Friedman, S. L. et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology 67, 1754\u20131767 (2018).","journal-title":"Hepatology"},{"key":"97439_CR25","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1515\/CCLM.1999.098","volume":"37","author":"T Yamaguchi","year":"1999","unstructured":"Yamaguchi, T. et al. Characterization of monoclonal antibodies to human protein 1\/Clara cell 10 kilodalton protein. Clin. Chem. Lab. Med. 37, 631\u2013637 (1999).","journal-title":"Clin. Chem. Lab. Med."},{"key":"97439_CR26","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/acem.13922","volume":"27","author":"WF Peacock","year":"2020","unstructured":"Peacock, W. F. et al. Myocardial infarction can be safely excluded by high-sensitivity troponin I testing 3 hours after emergency department presentation. Acad. Emerg. Med. 27, 671\u2013680 (2020).","journal-title":"Acad. Emerg. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97439-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97439-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97439-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T15:46:25Z","timestamp":1670082385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97439-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,14]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["97439"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-97439-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,14]]},"assertion":[{"value":"2 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18187"}}